Literature DB >> 26116958

Initial Experience of (68)Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy.

Lars Budäus1, Sami-Ramzi Leyh-Bannurah2, Georg Salomon3, Uwe Michl3, Hans Heinzer3, Hartwig Huland3, Markus Graefen3, Thomas Steuber3, Clemens Rosenbaum2.   

Abstract

UNLABELLED: Prostate-specific membrane antigen (PSMA) overexpression theoretically enables targeting of prostate cancer (PCa) metastases using gallium Ga 68 ((68)Ga)-labeled PSMA ligands for positron emission tomography/computed tomography (PET/CT) imaging. Promising detection rates have been reported when using this approach for functional imaging of recurrent PCa; however, until now, the diagnostic accuracy of (68)Ga-PSMA PET/CT for preoperatively identifying lymph node metastases (LNMs) had not been assessed. We retrospectively compared preoperative (68)Ga-PSMA PET/CT lymph node (LN) findings with histologic work-up after radical prostatectomy (RP). Overall, 608 LNs containing 53 LNMs were detected during RP. LNMs were present in 12 of 30 patients (40%). The (68)Ga-PSMA PET/CT scans identified 4 patients (33.3%) as LN true positive and 8 patients (66.7%) as false negative. Median size of (68)Ga-PSMA-PET/CT-detected versus undetected LNMs was 13.6 versus 4.3 mm (p<0.05). Overall sensitivity, specificity, positive predictive value, and negative predictive value of (68)Ga-PSMA PET/CT for LNM detection were 33.3%, 100%, 100%, and 69.2%, respectively. Per-side analyses revealed corresponding values of 27.3%, 100%, 100%, and 52.9%. Conversely, (68)Ga-PSMA PET/CT enabled tumor visualization in the prostate. In 92.9% of patients, the intraprostatic tumor foci were correctly predicted. Overall, (68)Ga-PSMA PET/CT is a promising tool for functional imaging; however, our initial experience revealed substantial influence of LNM size on the diagnostic accuracy of (68)Ga-PSMA PET/CT. PATIENT
SUMMARY: We assessed the diagnostic accuracy of (68)Ga-PSMA PET/CT in high-risk prostate cancer patients prior to radical prostatectomy. We found that lymph node metastasis detection rates were substantially influenced by lymph node metastasis size.
Copyright © 2015 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Imaging; Lymph node metastasis; Positron-emission tomography; Prostate cancer; Prostate-specific membrane antigen

Mesh:

Substances:

Year:  2015        PMID: 26116958     DOI: 10.1016/j.eururo.2015.06.010

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  120 in total

Review 1.  Anatomic and Molecular Imaging in Prostate Cancer.

Authors:  Eric T Miller; Amirali Salmasi; Robert E Reiter
Journal:  Cold Spring Harb Perspect Med       Date:  2018-03-01       Impact factor: 6.915

2.  Imaging and Characterization of Macrophage Distribution in Mouse Models of Human Prostate Cancer.

Authors:  Ben T Copeland; Hassan Shallal; Chentian Shen; Kenneth J Pienta; Catherine A Foss; Martin G Pomper
Journal:  Mol Imaging Biol       Date:  2019-12       Impact factor: 3.488

3.  [68Ga]PSMA PET/CT Improves Initial Staging and Management Plan of Patients with High-Risk Prostate Cancer.

Authors:  Nader Hirmas; Akram Al-Ibraheem; Ken Herrmann; Abedalatif Alsharif; Haider Muhsin; Jamal Khader; Ali Al-Daghmin; Samer Salah
Journal:  Mol Imaging Biol       Date:  2019-06       Impact factor: 3.488

Review 4.  Imaging of distant metastases of prostate cancer.

Authors:  Filippo Pesapane; Marcin Czarniecki; Matteo Basilio Suter; Baris Turkbey; Geert Villeirs
Journal:  Med Oncol       Date:  2018-09-14       Impact factor: 3.064

Review 5.  Metaanalysis of 68Ga-PSMA-11 PET Accuracy for the Detection of Prostate Cancer Validated by Histopathology.

Authors:  Thomas A Hope; Jeremy Z Goodman; Isabel E Allen; Jeremie Calais; Wolfgang P Fendler; Peter R Carroll
Journal:  J Nucl Med       Date:  2018-12-07       Impact factor: 10.057

6.  Preliminary results on response assessment using 68Ga-HBED-CC-PSMA PET/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapy.

Authors:  Anna Katharina Seitz; Isabel Rauscher; Bernhard Haller; Markus Krönke; Sophia Luther; Matthias M Heck; Thomas Horn; Jürgen E Gschwend; Markus Schwaiger; Matthias Eiber; Tobias Maurer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-11-28       Impact factor: 9.236

7.  Prostate Specific Membrane Antigen Targeted 18F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study.

Authors:  Michael A Gorin; Steven P Rowe; Hiten D Patel; Igor Vidal; Margarita Mana-Ay; Mehrbod S Javadi; Lilja B Solnes; Ashley E Ross; Edward M Schaeffer; Trinity J Bivalacqua; Alan W Partin; Kenneth J Pienta; Zsolt Szabo; Angelo M De Marzo; Martin G Pomper; Mohamad E Allaf
Journal:  J Urol       Date:  2017-07-20       Impact factor: 7.450

8.  Intraoperative 68Ga-PSMA Cerenkov Luminescence Imaging for Surgical Margins in Radical Prostatectomy: A Feasibility Study.

Authors:  Christopher Darr; Nina N Harke; Jan Philipp Radtke; Leubet Yirga; Claudia Kesch; Maarten R Grootendorst; Wolfgang P Fendler; Pedro Fragoso Costa; Christoph Rischpler; Christine Praus; Johannes Haubold; Henning Reis; Thomas Hager; Ken Herrmann; Ina Binse; Boris Hadaschik
Journal:  J Nucl Med       Date:  2020-02-14       Impact factor: 10.057

Review 9.  PET imaging for lymph node dissection in prostate cancer.

Authors:  Elena Incerti; Paola Mapelli; Luigi Gianolli; Maria Picchio
Journal:  World J Urol       Date:  2016-10-17       Impact factor: 4.226

Review 10.  [Focus on molecular imaging in prostate cancer].

Authors:  L Michaud; K A Touijer
Journal:  Prog Urol       Date:  2016-09-20       Impact factor: 0.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.